سعر ايسينتريس 400مجم 60 قرص 2026

Isentress 400 mg film-coated tablets, pack of 60 (raltegravir), by Merck Sharp & Dohme (MSD), marketed in Egypt as an HIV-1 antiretroviral. Egyptian leaflet not opened; clinical content below is from the US DailyMed label for the same brand/strength film-coated tablet.

• Treatment of HIV-1 infection in combination with other antiretroviral agents in adults.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Treatment of HIV-1 infection in combination with other antiretroviral agents in paediatric patients weighing at least 2 kg (ISENTRESS; ISENTRESS HD from 40 kg).Population: Paediatric patients ≥2 kgDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions of moderate to severe intensity (≥2%) include insomnia, headache, dizziness, nausea and fatigue.International label, same product · DailyMed (U.S. National Library of Medicine)

• None listed in the US label.International label, same product · DailyMed (U.S. National Library of Medicine)

• Severe, potentially life-threatening and fatal skin reactions (including Stevens-Johnson syndrome and toxic epidermal necrolysis) and hypersensitivity reactions (rash with constitutional findings and sometimes organ dysfunction including hepatic failure) have been reported. Discontinue ISENTRESS/ISENTRESS HD and other suspect agents immediately if severe rash or hypersensitivity develops; monitor clinical status including liver aminotransferases.International label, same product · DailyMed (U.S. National Library of Medicine)
• Immune reconstitution syndrome has been reported with combination antiretroviral therapy including ISENTRESS; patients may develop inflammatory responses to residual opportunistic infections, and autoimmune disorders have been reported months after treatment initiation.International label, same product · DailyMed (U.S. National Library of Medicine)
• ISENTRESS chewable tablets contain phenylalanine (aspartame) and can be harmful in phenylketonuria; not applicable to the Egyptian 400 mg film-coated tablets pack researched here.International label, same product · DailyMed (U.S. National Library of Medicine)

• Aluminum- and/or magnesium-containing antacidsCoadministration or staggered administration with ISENTRESS is not recommended (decreases raltegravir). Calcium carbonate antacid: no dose adjustment for ISENTRESS 400 mg; coadministration not recommended for ISENTRESS HD.DailyMed (U.S. National Library of Medicine)
• RifampinInduces UGT1A1 and decreases raltegravir; recommended ISENTRESS dosage during coadministration is 800 mg twice daily. Coadministration of ISENTRESS HD with rifampin is not recommended. No data to guide coadministration of ISENTRESS with rifampin below 18 years of age.DailyMed (U.S. National Library of Medicine)
• Tipranavir/ritonavirNo dose adjustment for ISENTRESS 400 mg; coadministration not recommended for ISENTRESS HD.DailyMed (U.S. National Library of Medicine)

• Available data from the Antiretroviral Pregnancy Registry (APR) show no difference in the rate of overall birth defects for raltegravir compared with the background rate of major birth defects (2.7%) in the US MACDP reference population. Animal studies showed no evidence of adverse developmental outcomes at exposures up to ~4× the MRHD of 1200 mg.International label, same product · DailyMed (U.S. National Library of Medicine)
• CDC recommends that HIV-1 infected mothers in the United States not breastfeed their infants to avoid postnatal HIV-1 transmission. There are no data on presence of raltegravir in human milk; instruct mothers not to breastfeed if receiving ISENTRESS/ISENTRESS HD (HIV transmission, viral resistance, and adverse reactions risks).International label, same product · DailyMed (U.S. National Library of Medicine)

• Raltegravir: Inhibits HIV-1 integrase strand transfer, blocking viral DNA integration into the host genome.